Pharmaceuticals

Global Epkinly Market 2026–2030: Forecast Insights for Business Planning

March 5, 2026March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the epkinly market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Epkinly Market in 2030?

Historical expansion was driven by a growing prevalence of non-Hodgkin lymphoma, the limitations inherent in traditional chemotherapy, developments in monoclonal antibody research, an increase in approvals for targeted oncology medications, and the unaddressed demands within relapsed cancer treatment.

Growth within the forecast period is expected to arise from the increasing adoption of immuno-oncology therapies, the widening clinical applications for bispecific antibodies, improved patient outcome data, a rise in oncology healthcare spending, and the establishment of more specialty cancer centers. Key trends identified for this forecast period encompass bispecific antibody immunotherapies, the broader use of T-cell engaging oncology drugs, a particular emphasis on relapsed and refractory lymphomas, the administration of oncology drugs via subcutaneous routes, and personalized treatments for hematologic cancers.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20060&type=smp

What Drivers Are Influencing Production Trends In The Epkinly Market?

The epkinly market is anticipated to expand in the future due to the escalating demand for targeted therapies. These therapies are precise treatments that block specific molecules driving diseases, especially cancers, offering fewer side effects than traditional treatments. The increase in targeted therapies is attributed to their capability to provide more effective, personalized treatments with reduced adverse effects. Epkinly (epcoritamab) is utilized in targeted therapy for relapsed or refractory B-cell non-Hodgkin lymphoma by binding CD3 on T cells and CD20 on B cells, thus directing the immune system to destroy cancerous B cells. For instance, in October 2024, according to the National Health Service, a UK-based government department, 14.5% of HRT (hormone replacement therapy) items in 2023/24 were associated with an HRT prescription prepayment certificate (PPC). By June 2024, this proportion had risen to 21%, which is higher compared to 9.7% in June 2023. Therefore, the increasing demand for targeted therapies is driving the growth of the epkinly market.

Which Segment Groups Are Influencing The Epkinly Market?

The epkinly market covered in this report is segmented –

1) By Indication: Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma (HGBL), Indolent Lymphoma

2) By Route Of Administration: Intravenous (IV), Subcutaneous (SC)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies

Which Trends Are Shaping Activity Within The Epkinly Market?

A key trend in the epkinly market involves obtaining regulatory approvals for groundbreaking therapies, particularly bispecific antibody therapies, to enhance treatment efficacy and expand therapeutic options. Bispecific antibody therapies are a form of immunotherapy where antibodies are engineered to bind simultaneously to two different antigens or targets. For instance, in June 2024, AbbVie Inc., a US-based biotech company, secured FDA approval for EPKINLY (epcoritamab-bysp), which is the first bispecific antibody for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This innovative treatment engages the immune system by targeting CD20 and CD3, achieving an impressive overall response rate of 82% in clinical trials. Administered subcutaneously with a step-up dosing regimen, EPKINLY provides a new option for patients who have limited alternatives. This approval represents a significant advancement in the management of follicular lymphoma, offering hope for improved patient outcomes.

Who Are The Major Companies Operating In The Epkinly Market?

Major companies operating in the epkinly market are AbbVie Inc., Genmab A/S.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/epkinly-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Epkinly Market?

North America was the largest region in the epkinly market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the epkinly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Epkinly Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20060&type=smp

Browse Through More Reports Similar to the Global Epkinly Market 2026, By The Business Research Company

Epoxy Primer Market Report 2026

https://www.thebusinessresearchcompany.com/report/epoxy-primer-global-market-report

Exchange Traded Fund Market Report 2026

https://www.thebusinessresearchcompany.com/report/exchange-traded-fund-global-market-report

Solar Epc Market Report 2026

https://www.thebusinessresearchcompany.com/report/solar-epc-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795